Analysts expect that ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will announce $48.46 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for ANI Pharmaceuticals’ earnings, with estimates ranging from $48.41 million to $48.50 million. ANI Pharmaceuticals reported sales of $38.53 million in the same quarter last year, which indicates a positive year-over-year growth rate of 25.8%. The business is expected to report its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that ANI Pharmaceuticals will report full-year sales of $48.46 million for the current financial year, with estimates ranging from $183.23 million to $183.40 million. For the next financial year, analysts expect that the company will post sales of $215.95 million per share, with estimates ranging from $205.90 million to $226.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.19. The company had revenue of $44.80 million during the quarter, compared to analyst estimates of $43.20 million. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The firm’s revenue was up 43.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.11 earnings per share.

Several analysts recently issued reports on ANIP shares. Canaccord Genuity started coverage on ANI Pharmaceuticals in a report on Monday, July 31st. They set a “buy” rating and a $60.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $80.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, BidaskClub upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $65.33.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded up 0.39% during midday trading on Friday, reaching $53.58. The company’s stock had a trading volume of 32,341 shares. The stock has a 50-day moving average price of $49.37 and a 200 day moving average price of $48.08. ANI Pharmaceuticals has a 52 week low of $42.23 and a 52 week high of $69.71. The stock has a market capitalization of $623.56 million, a PE ratio of 117.24 and a beta of 3.05.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Texas Permanent School Fund raised its holdings in ANI Pharmaceuticals by 1.9% during the second quarter. Texas Permanent School Fund now owns 5,863 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 111 shares in the last quarter. Prudential Financial Inc. raised its holdings in ANI Pharmaceuticals by 1.4% during the first quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock valued at $697,000 after buying an additional 200 shares in the last quarter. Thrivent Financial For Lutherans raised its holdings in ANI Pharmaceuticals by 5.1% during the first quarter. Thrivent Financial For Lutherans now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 220 shares in the last quarter. Comerica Bank raised its holdings in ANI Pharmaceuticals by 3.8% during the first quarter. Comerica Bank now owns 8,855 shares of the specialty pharmaceutical company’s stock valued at $486,000 after buying an additional 323 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in ANI Pharmaceuticals by 0.6% during the second quarter. Ameriprise Financial Inc. now owns 54,205 shares of the specialty pharmaceutical company’s stock valued at $2,536,000 after buying an additional 340 shares in the last quarter. Institutional investors own 55.86% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/06/zacks-analysts-expect-ani-pharmaceuticals-inc-anip-will-announce-quarterly-sales-of-48-46-million.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.